...

Expert Analysis

Investigational Antiretrovirals

Source: CCO Independent Conference Coverage of the 2003 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Investigational Antiretrovirals


Program Director: John P. Phair, MD

Faculty:

Joseph J. Eron, Jr., MDW. David Hardy, MDWilliam G. Powderly, MD
  • Joseph J. Eron, Jr., MD
  • W. David Hardy, MD
  • William G. Powderly, MD

CREDIT INFORMATION

Release Date: March 12, 2003

Expiration Date: March 11, 2004


Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: The activity is not currently available for credit.

Begin the Expert Analysis

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify 2 protease inhibitors in development that have activity against HIV-1 that is resistant to currently available protease inhibitors

  • Discuss the activity of T-1249, a fusion inhibitor in development, in patients with HIV-1 resistant to T-20

  • Describe at least 2 mechanisms of action by which new antiretroviral agents inhibit HIV replication


Earn CME credit by reading the expert analysis and commentary on the antiretroviral management of patients receiving therapy. Topics covered include:

  • Tipranavir
  • Fosamprenavir
  • Emtricitabine
  • T-1249
  • TMC114
  • Amdoxovir
  • TNX-355
  • CCR5 Inhibitors
  • PA-457
  • Conclusion: How healthy is the drug development pipeline?
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.